Akèy › Dematit atopik (Ekzema) › Indiana
Etid klinik pou Dematit atopik (Ekzema) nan Indiana
9 etid pou Dematit atopik (Ekzema) ap chèche patisipan nan sit nan Indiana.
Vil nan Indiana
Tèks ofisyèl etid la (Anglè)
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Clinical Site 106, Plainfield
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 29, 2026 · NCT07453602Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Clarksville
- Enveda Investigative Site, New Albany
- Enveda Investigative Site, West Lafayette
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Ap rekriteFaz 3
Laj 2 a 11 · Tout sèks · Mizajou Sep 25, 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- DS Research of Southern Indiana,LLC, Clarksville
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Aug 28, 2026 · NCT07599813A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Indianapolis
- Enveda Investigative Site, Plainfield
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07643766A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Dawes Fretzin /ID# 265097, Indianapolis
Ap rekriteFaz 3
Laj 2 a 11 · Tout sèks · Mizajou Aug 6, 2026 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Options Research Group /ID# 264564, West Lafayette
Ap rekriteFaz 3
Laj 18 a 63 · Tout sèks · Mizajou Jul 6, 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- Southern Indiana Clinical Trials, New Albany
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 4, 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 8142, Indianapolis
- Galderma Investigational Site 7083, West Lafayette
Ap rekriteEtid obsèvasyon
Laj 12 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT06988605Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.